Abstract
Ribozymes are a new pharmaceutical class of reagents that offer potential in treating a number of different medical disorders, including infectious diseases and cancer. As a first step towards using ribozymes for the treatment of liver disorders such as viral hepatitis, adenovirus vectors that contain a ribozyme expression cassette under the control of different promoters directed against human growth hormone (hGH) were constructed and infused into transgenic mice that produce hGH from the gastrointestinal tract and liver. Adenovirus-mediated transfer of expressed ribozymes resulted in up to a 96% reduction of hepatic hGH mRNA over a period of several weeks in the transgenic mouse model. Furthermore, the concentration of ribozyme RNA correlated with the degree of hGH mRNA reduction. This study clearly demonstrates that ribozymes can function during the period of expression in an intact organ after somatic gene transfer.
Full Text
The Full Text of this article is available as a PDF (230.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Durnam D. M., Palmiter R. D. A practical approach for quantitating specific mRNAs by solution hybridization. Anal Biochem. 1983 Jun;131(2):385–393. doi: 10.1016/0003-2697(83)90188-4. [DOI] [PubMed] [Google Scholar]
- Engelhardt J. F., Ye X., Doranz B., Wilson J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6196–6200. doi: 10.1073/pnas.91.13.6196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fang B., Eisensmith R. C., Li X. H., Finegold M. J., Shedlovsky A., Dove W., Woo S. L. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther. 1994 Jul;1(4):247–254. [PubMed] [Google Scholar]
- Feng M., Cabrera G., Deshane J., Scanlon K. J., Curiel D. T. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 1995 May 15;55(10):2024–2028. [PubMed] [Google Scholar]
- Kay M. A., Graham F., Leland F., Woo S. L. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology. 1995 Mar;21(3):815–819. [PubMed] [Google Scholar]
- Kay M. A., Holterman A. X., Meuse L., Gown A., Ochs H. D., Linsley P. S., Wilson C. B. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet. 1995 Oct;11(2):191–197. doi: 10.1038/ng1095-191. [DOI] [PubMed] [Google Scholar]
- Kay M. A., Woo S. L. Gene therapy for metabolic disorders. Trends Genet. 1994 Jul;10(7):253–257. doi: 10.1016/0168-9525(94)90173-2. [DOI] [PubMed] [Google Scholar]
- Larsson S., Hotchkiss G., Andäng M., Nyholm T., Inzunza J., Jansson I., Ahrlund-Richter L. Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res. 1994 Jun 25;22(12):2242–2248. doi: 10.1093/nar/22.12.2242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li Q., Kay M. A., Finegold M., Stratford-Perricaudet L. D., Woo S. L. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther. 1993 Aug;4(4):403–409. doi: 10.1089/hum.1993.4.4-403. [DOI] [PubMed] [Google Scholar]
- Lieber A., Kiessling U., Strauss M. High level gene expression in mammalian cells by a nuclear T7-phase RNA polymerase. Nucleic Acids Res. 1989 Nov 11;17(21):8485–8493. doi: 10.1093/nar/17.21.8485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lieber A., Sandig V., Sommer W., Bähring S., Strauss M. Stable high-level gene expression in mammalian cells by T7 phage RNA polymerase. Methods Enzymol. 1993;217:47–66. doi: 10.1016/0076-6879(93)17055-a. [DOI] [PubMed] [Google Scholar]
- Lieber A., Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol. 1995 Jan;15(1):540–551. doi: 10.1128/mcb.15.1.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Poeschla E., Wong-Staal F. Antiviral and anticancer ribozymes. Curr Opin Oncol. 1994 Nov;6(6):601–606. doi: 10.1097/00001622-199411000-00012. [DOI] [PubMed] [Google Scholar]
- Scaria A., Curiel D. T., Kay M. A. Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. Gene Ther. 1995 Jun;2(4):295–298. [PubMed] [Google Scholar]
- Simon T. C., Roth K. A., Gordon J. I. Use of transgenic mice to map cis-acting elements in the liver fatty acid-binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spatial patterns of expression in the gut epithelium and in the liver acinus. J Biol Chem. 1993 Aug 25;268(24):18345–18358. [PubMed] [Google Scholar]
- Spessot R., Inchley K., Hupel T. M., Bacchetti S. Cloning of the herpes simplex virus ICP4 gene in an adenovirus vector: effects on adenovirus gene expression and replication. Virology. 1989 Feb;168(2):378–387. doi: 10.1016/0042-6822(89)90279-1. [DOI] [PubMed] [Google Scholar]
- Sullivan S. M. Development of ribozymes for gene therapy. J Invest Dermatol. 1994 Nov;103(5 Suppl):85S–89S. doi: 10.1038/jid.1994.15. [DOI] [PubMed] [Google Scholar]
- Townes T. M., Lingrel J. B., Chen H. Y., Brinster R. L., Palmiter R. D. Erythroid-specific expression of human beta-globin genes in transgenic mice. EMBO J. 1985 Jul;4(7):1715–1723. doi: 10.1002/j.1460-2075.1985.tb03841.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vrancken Peeters M. J., Perkins A. L., Kay M. A. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques. 1996 Feb;20(2):278–285. doi: 10.2144/96202rr05. [DOI] [PubMed] [Google Scholar]